Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.93)
# 172
Out of 4,639 analysts
238
Total ratings
65.5%
Success rate
41.8%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Rated: Buy | $235 → $260 | $250.09 | +3.96% | 18 | Aug 10, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Hold | $19 | $18.22 | +4.28% | 28 | Aug 10, 2026 | |
| TVTX Travere Therapeutics | Rated: Buy | $68 → $78 | $60.21 | +29.55% | 9 | Aug 10, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $33 | $26.96 | +22.40% | 5 | Aug 10, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $26 | $22.97 | +13.19% | 12 | Aug 10, 2026 | |
| TENX Tenax Therapeutics | Downgraded: Hold | $39 → $5 | $1.62 | +208.64% | 2 | Aug 10, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $120 → $134 | $108.49 | +23.51% | 10 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $21 | $13.38 | +56.95% | 6 | Aug 10, 2026 | |
| EVMN Evommune | Maintained: Buy | $55 → $22 | $14.21 | +54.82% | 4 | Aug 10, 2026 | |
| INSM Insmed | Maintained: Buy | $208 → $170 | $132.57 | +28.23% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $329 | $254.57 | +29.24% | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $65 → $77 | $76.87 | +0.17% | 4 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,059 | $864.74 | +22.46% | 13 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 | $26.71 | +23.55% | 7 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $91 | $30.29 | +200.43% | 8 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $88 → $85 | $84.36 | +0.76% | 6 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8931 | - | 8 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.38 | - | 7 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $35.46 | +43.82% | 1 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $126 → $138 | $98.23 | +40.49% | 19 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $295 → $300 | $327.05 | -8.27% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $18 | $13.05 | +37.93% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $30.36 | +51.52% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $26 | $40.91 | -36.45% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $10.34 | +64.41% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.92 | +160.42% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $3.50 | +42.86% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $1.23 | +225.20% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.79 | +43.37% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $6.59 | n/a | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.87 | n/a | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $78 | $121.07 | n/a | 1 | Aug 3, 2022 |
AbbVie
Aug 10, 2026
Rated: Buy
Price Target: $235 → $260
Current: $250.09
Upside: +3.96%
Sarepta Therapeutics
Aug 10, 2026
Maintained: Hold
Price Target: $19
Current: $18.22
Upside: +4.28%
Travere Therapeutics
Aug 10, 2026
Rated: Buy
Price Target: $68 → $78
Current: $60.21
Upside: +29.55%
Ultragenyx Pharmaceutical
Aug 10, 2026
Maintained: Buy
Price Target: $33
Current: $26.96
Upside: +22.40%
Viridian Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $26
Current: $22.97
Upside: +13.19%
Tenax Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: $39 → $5
Current: $1.62
Upside: +208.64%
Dianthus Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $120 → $134
Current: $108.49
Upside: +23.51%
COMPASS Pathways
Aug 10, 2026
Maintained: Buy
Price Target: $21
Current: $13.38
Upside: +56.95%
Evommune
Aug 10, 2026
Maintained: Buy
Price Target: $55 → $22
Current: $14.21
Upside: +54.82%
Insmed
Aug 7, 2026
Maintained: Buy
Price Target: $208 → $170
Current: $132.57
Upside: +28.23%
Aug 7, 2026
Maintained: Buy
Price Target: $329
Current: $254.57
Upside: +29.24%
Jul 27, 2026
Downgraded: Hold
Price Target: $65 → $77
Current: $76.87
Upside: +0.17%
Jul 27, 2026
Maintained: Buy
Price Target: $1,059
Current: $864.74
Upside: +22.46%
Jul 27, 2026
Maintained: Buy
Price Target: $33
Current: $26.71
Upside: +23.55%
Jul 9, 2026
Maintained: Buy
Price Target: $91
Current: $30.29
Upside: +200.43%
Jul 8, 2026
Downgraded: Hold
Price Target: $88 → $85
Current: $84.36
Upside: +0.76%
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $0.8931
Upside: -
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $16.38
Upside: -
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $35.46
Upside: +43.82%
May 7, 2026
Maintained: Buy
Price Target: $126 → $138
Current: $98.23
Upside: +40.49%
May 5, 2026
Maintained: Buy
Price Target: $295 → $300
Current: $327.05
Upside: -8.27%
Apr 1, 2026
Maintained: Buy
Price Target: $20 → $18
Current: $13.05
Upside: +37.93%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $30.36
Upside: +51.52%
Mar 2, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $40.91
Upside: -36.45%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $10.34
Upside: +64.41%
Dec 17, 2025
Maintained: Buy
Price Target: $5
Current: $1.92
Upside: +160.42%
Dec 17, 2025
Maintained: Hold
Price Target: $5
Current: $3.50
Upside: +42.86%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $1.23
Upside: +225.20%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $2.79
Upside: +43.37%
Dec 20, 2024
Reiterated: Buy
Price Target: $20 → $18
Current: $6.59
Upside: n/a
May 30, 2023
Maintained: Buy
Price Target: $10
Current: $3.87
Upside: n/a
Aug 3, 2022
Downgraded: Hold
Price Target: $78
Current: $121.07
Upside: n/a